P530 Ultra-proactive therapeutic drug monitoring incorporating infliximab point-of-care testing with ad hoc dose adjustment reduces C-reactive protein levels in patients with IBD during infliximab maintenance treatment
2019 ◽
Vol 13
(Supplement_1)
◽
pp. S378-S378
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2018 ◽
Vol 7
(1)
◽
2018 ◽
Vol 202
◽
pp. 1-12
◽
Keyword(s):